13F Holdings
中文EN

HAE HAEMONETICS CORP

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 313143 · Fiscal year ends 04/03

Financial factors as of 2026-09-26 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.1%
TTM net income YoY-38.2%
TTM EPS YoY-33.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR-6.8%

Margins

Gross margin59.6%
Operating margin12.8%
Net margin7.5%
FCF margin21.6%
EBITDA margin20.7%

Returns

ROE11.9%
ROA4.3%
ROIC (approx.)7.3%
Asset turnover0.57x

Leverage & solvency

Liabilities / assets62.7%
Debt / equity1.25x
Current ratio2.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.32x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue3.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-28FY20252025-03-29FY20242024-03-30FY20232023-04-01FY20222022-04-02
Income statement
Revenue$1.33B$1.36B$1.31B$1.17B$993.20M
Cost of revenue$546.44M$611.87M$617.51M$553.56M$487.69M
Gross profit$787.59M$748.96M$691.55M$615.10M$505.50M
R&D expense$59.77M$62.72M$54.44M$50.13M$46.80M
SG&A expense$442.42M$436.79M$429.78M$376.68M$340.14M
Operating income$156.73M$221.82M$164.88M$156.03M$80.75M
Interest expense$19.30M$35.90M$19.50M$13.00M$5.80M
Pretax income$128.03M$212.07M$151.87M$141.40M$63.63M
Income tax$30.72M$44.39M$34.31M$26.00M$20.25M
Net income$97.31M$167.68M$117.56M$115.40M$43.38M
EBITDA$268.45M$337.40M$262.10M$249.34M$178.50M
EPS (basic)2.063.332.322.270.85
EPS (diluted)2.053.312.292.240.84
Weighted avg. shares (diluted)47.35M50.73M51.40M51.42M51.35M
Balance sheet
Cash & equivalents$245.44M$306.76M$178.80M$284.47M$259.50M
Receivables$216.85M$202.66M$206.56M$179.14M$159.38M
Inventory$306.37M$365.14M$317.20M$259.38M$293.03M
Current assets$834.88M$934.98M$768.90M$769.72M$756.03M
PP&E, net$305.76M$284.05M$311.36M$310.88M$258.48M
Goodwill$656.37M$604.27M$565.08M$466.23M$467.29M
Intangibles$447.65M$455.74M$406.12M$275.77M$310.26M
Total assets$2.40B$2.45B$2.20B$1.93B$1.86B
Current liabilities$282.60M$578.11M$300.38M$251.82M$442.27M
Short-term debt$5.01M$303.56M$10.23M$11.78M$214.15M
Long-term debt$1.22B$921.23M$797.56M$754.10M$559.44M
Total debt$1.22B$1.22B$807.79M$765.89M$773.59M
Total liabilities$1.60B$1.63B$1.24B$1.12B$1.11B
Shareholders' equity$796.32M$820.84M$959.96M$818.00M$749.42M
Net debt$979.14M$918.02M$628.99M$481.42M$514.09M
Shares outstanding45.25M48.22M50.79M50.45M51.12M
Cash flow statement
Operating cash flow$293.22M$181.72M$181.75M$273.06M$172.26M
Capital expenditure$32.78M$39.28M$38.12M$191.33M$96.51M
Free cash flow$260.44M$142.45M$143.63M$81.73M$75.75M
Investing cash flow-$179.55M-$161.90M-$322.39M-$143.79M-$86.34M
Financing cash flow-$178.46M$108.82M$38.16M-$100.36M-$15.75M
Depreciation & amortization$111.72M$115.59M$97.22M$93.31M$97.75M
Stock-based compensation$33.83M$29.64M$28.33M$25.58M$24.36M
Share buybacks$175.00M$225.00M$0$75.00M$0

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.